Oct. 23, 2020 Price forecast | 2 weeks: 5.89% | 1 month: 2.56% | 3 months: -3.23%

SELB stock forecast

Our latest prediction for Selecta Biosciences Inc's stock price was made on the Oct. 23, 2020 when the stock price was at 2.83$.

In the short term (2weeks), SELB's stock price should outperform the market by 5.89%. During that period the price should oscillate between -11.80% and +24.75%.

In the medium term (3months), SELB's stock price should underperform the market by -3.23%. During that period the price should oscillate between -45.91% and +46.87%.

Create a solid portfolio with SELB

Add SELB to your portfolio and optimize it!

About Selecta Biosciences Inc

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation.[failed verification] PacBio describes its platform as single molecule real time sequencing , based on the properties of zero-mode waveguides. The company's first commercial product, the PacBio RS, was sold to a limited set of customers in 2010 and was commercially released in early 2011. A subsequent version of the sequencer called the PacBio RS II was released in April 2013. On September 25, 2013 a partnership between Pacific Biosciences and Roche Diagnostics was announced for the development of in vitro diagnostic products using the technology, with Roche providing US$75,000,000 in the deal. In 2015, the company launched a new sequencing instrument called the Sequel System with approximately 7-fold greater capacity than the PacBio RS II. Then in April 2019 the company launched the Sequel II system with a further 8-fold increase in throughput. The company was founded based on research done at Cornell University that combined semiconductor processing and photonics with biotechnology research. Three graduate students in the lab of Professor Harold Craighead — Steve Turner, Jonas Korlach, and Mathieu Foquet — became the first employees.

At the moment the company generates 7M USD in revenues.

On its last earning announcement, the company reported a loss of -1.00$ per share.

The book value per share is 1.08$

Selecta Biosciences Inc website

Three months stock forecastOct. 23, 2020


Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
7M - -60M -895.00% -71M -1.00 - - 73M 1.08 -48M - -48M